Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Date:12/15/2008

SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by Arena that targets the glucose-dependent insulinotropic receptor (GDIR) for the treatment of type 2 diabetes. The GDIR was also discovered by Arena and has the potential to stimulate insulin release in response to increases in blood glucose.

"The GDIR is a promising and exciting target for the treatment of type 2 diabetes. We look forward to continuing to work with Ortho-McNeil on APD597 as it advances in the clinic," stated Jack Lief, Arena's President and Chief Executive Officer.

Ortho-McNeil's Phase 1 program will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597 in single and multiple ascending dose studies in healthy volunteers. Ortho-McNeil's planned clinical studies will also include the evaluation of patients with type 2 diabetes.

Aboutthe Glucose-Dependent Insulinotropic Receptor (GDIR)

The GDIR is an orphan G protein-coupled receptor (GPCR), discovered by Arena. It is expressed in beta cells, the cells in the pancreas responsible for producing insulin in response to increases in blood glucose. The GDIR signals through a similar intracellular pathway as the GLP-1 receptor, with common downstream effects, but unlike the GLP-1 receptor, the GDIR has proven amenable to small molecule drug discovery. Stimulation of the GDIR is intended to more efficiently promote insulin release by beta cells in response to elevated blood glucose levels. In addition, the GDIR is expressed in cells other than pancreatic beta cells, such as endocrine cells in the gastrointest
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Z-Medica, a leading developer and marketer of ... line of products designed to meet the unique needs ... EMS 4x4 Dressing, QuikClot ® EMS TraumaPad ... all custom-designed to help responders stop bleeding fast and ... a hospital or trauma center. The line includes products ...
(Date:5/22/2013)... , May 22, 2013 MEDIFIRST SOLUTIONS, ... to update shareholders about some recent company developments. As ... its avenues of communication with shareholders. Integrating social media ... a Facebook page and will post updates on Twitter.  ... hashtag is #medifirstusa. Says CEO ...
(Date:5/22/2013)... , May 22, 2013  Flagship Ventures, a ... on healthcare and sustainability, today announced the appointment ... a Senior Partner. In this role, Mr. Bancel ... companies. In addition to working closely ... also serves as President and Chief Executive Officer ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2Medifirst Solutions, Inc. Announces Update To Shareholders 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3
... Nov. 18 Starpharma Holdings Limited (ASX: SPL; OTCQX: ... of A$15.6 million through a private placement to institutional ... approximately A$24 million. , The lead investor in the ... highly regarded institutional fund manager. As a result ...
... , SAN DIEGO, Nov. 18 Rules-Based Medicine, Inc. ... and services agreement with Covance Inc. (NYSE: CVD ... powerful combination of biomarker technologies and services for use in ... RBM as its exclusive third-party provider of multiplexed protein biomarker ...
Cached Medicine Technology:Starpharma Announces $15.6 million Capital Raising 2Starpharma Announces $15.6 million Capital Raising 3Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:5/22/2013)... Illinois researcher says that the cornerstone of our efforts ... people to participate in the Supplemental Nutrition Assistance Program ... SNAP, formerly known as the Food Stamp Program, is ... additional improvements could be even more successful at reducing ... of I professor of agricultural and consumer economics and ...
(Date:5/22/2013)... of up to 1,000 mg per day can help ... author was Lisa Langsetmo, a Ph.D. Research Associate at ... Goltzman, Division of Endocrinology and Metabolism in the Department ... in the Musculoskeletal Disorders axis at the Research Institute ... published in the Journal of Clinical Endocrinology & ...
(Date:5/22/2013)... parents are married are less likely to be obese, ... University of Houston. , "Childhood obesity is a significant ... of all U.S. children ages 2-17 overweight or obese," ... at Rice and director of Rice,s Kinder Institute Urban ... conducted to explore the impact of family structure on ...
(Date:5/22/2013)... 22, 2012 (Hackensack, NJ) John Theurer Cancer Center at ... 50 cancer centers, will bring together leading cancer experts, ... implications of cell therapy and interventional immunology in oncology, ... , "I,m excited to bring together some of the ... and implications of cell therapies in oncology, both in ...
(Date:5/22/2013)... Garcinia cambogia select is a dual action fat ... extra fat being stored in the body. For a rapid ... fat burner helps people in this regard by making the ... it does this by secreting a hormone serotonin which makes ... from emotional overeating. In this way, it keeps a control ...
Breaking Medicine News(10 mins):Health News:Alleviating hunger in the US -- researcher says, it's a SNAP 2Health News:Alleviating hunger in the US -- researcher says, it's a SNAP 3Health News:Calcium supplements linked to longer lifespans in women 2Health News:Children of married parents less likely to be obese 2Health News:Children of married parents less likely to be obese 3Health News:Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies 2Health News:Garcinia Cambogia Reviews Released Online for Fast Weight Loss Solution with Offer of Extra 3 Month Supply 2
... A researcher at Tulane University, Marie Krousel-Wood says people ... taking blood pressure medications than others. And people who ... report less intake of BP drugs. ,‘Nationally ... high blood pressure have the condition under control. Poor ...
... quota in Central educational institutions, Union Health Minister Ambumani ... media creation // and that the government's decision ... resistance was all by the media,' Ramadoss told newspersons ... the government proposal, he said 'This is in accordance ...
... cases of jaundice were detected here today even as ... to be suffering from the disease. // ... Nagar found four persons including two children were suffering ... the civil surgeon visited the area as doctors collected ...
... time women will have a vaccine to protect themselves from ... of 'Gardasil' produced by American pharmaceutical giant Merck. // ... of the vaccine, Gardasil, for use in girls and women ... allows an early release of products with potential to provide ...
... Recent research has revealed that taking antibiotics for three days ... is equally effective in the treatment of common pneumonia // ... to curb the rising problem of antibiotic-resistant bacteria, ... diseases at the Academic Medical Center, in Amsterdam said,’The question ...
... state and federal, experts warn that many million dollars ... // . ,A psychiatrist, Ian Hickie says ... were having clash in setting policies. ,The ... due to lack of clear accountability, federal-state role in ...
Cached Medicine News:Health News:Pneumonia Effectively Treated with Short-Term Antibiotic Course 2
... IM3300 EDTV Autoclavable 3CCD Video System, our newly ... truly innovative design features. Operation of the LS7500 ... to operate. To improve the safety of the ... which allows an extra layer of control before ...
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio...
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
Conducting disposable filter-tips....
Medicine Products: